NEW YORK, May 12, 2017 /PRNewswire/ -- Saturday marks the official first day of the XVII International Workshop on Chronic Lymphocytic Leukemia (iwCLL) biennial meeting at the Times Square Marriott in New York City. For more than 30 years, the iwCLL meetings have focused on bringing together international leaders in the understanding and treatment of chronic lymphocytic leukemia (CLL), which is the most common type of leukemia in adults. As the world's leading member-driven organization dedicated to the field of CLL and related lymphoproliferative disorders, iwCLL assembles speakers from scientific research, clinical medicine, and pharmaceutical and biotechnology industries to advance the science and care of people with CLL and lymphoprolferative disorders.
"iwCLL 2017 provides an opportunity for the community to come together in a focused way and discuss the current thinking and discoveries in the field," said Nicholas Chiorazzi, MD, Meeting and Program Chair. "For those of us committed to understanding and treating CLL and related lymphoproliferative disorders, the promising advances that have made their way from the lab and the clinic in the past few years have reignited our enthusiasm and dedication to finding a cure for this disease. Science is not carried out alone. It requires the sharing of ideas, the thoughtful input from peers, and collaborations among disciplines to bring forward new approaches to reach even longer survival for more patients living with this disease."
The 2017 iwCLL program and special sessions are organized around the following themes: current understanding of factors that contribute to the development of CLL; emerging evidence regarding the diagnosis, prognosis, and initial treatment of CLL; parameters contributing to disease evolution and progression; and emerging research in treating advanced disease. This year, more than 200 abstracts were accepted for presentation at the meeting. The titles for these abstracts are publicly posted on iwCLL2017.org and abstracts will be available for meeting attendees via the conference app.
For more information on registration or to view the full list of abstract titles, visit the iwCLL website at www.iwCLL2017.org; email iwCLL2017@bioascend.com or connect with us on Twitter (@iwCLL), Facebook, or LinkedIn.
About Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia, also called CLL, is a blood and bone marrow disease that usually gets worse slowly. CLL is the most common type of leukemia in adults. It often occurs during or after middle age. The average age at the time of diagnosis is around 71 years and it is rarely seen in people under age 40. CLL accounts for about one-quarter of the new cases of leukemia. The average person's lifetime risk of getting CLL is about 1 in 200. The risk is slightly higher in men than in women. CLL mainly affects older adults.
About International Workshop on Chronic Lymphocytic Leukemia
The International Workshop on Chronic Lymphocytic Leukemia, or iwCLL, is a biennial meeting focused solely on advancing the understanding and treatment of CLL and related lymphoproliferative disorders. Founded in 1979, iwCLL is now the largest international meeting dedicated to advancing state-of-the-art and emerging concepts – from laboratory-based research to the clinic – in the pathobiology and treatment of these blood cancers. The meeting is intended to provide a forum that promotes the exchange of information and encourages collaboration among international leaders and scientists interested in CLL and lymphoproliferative disorders.
For Media Inquiries Contact:
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-largest-international-assembly-on-chronic-lymphocytic-leukemia-cll-kicks-off-its-17th-biennial-meeting-in-new-york-city-300456521.html
SOURCE International Workshop on Chronic Lymphocytic Leukemia